Cramer’s Stock Picks: Why He’s Avoiding IonQ and Embracing Kimberly-Clark

In the fast-paced world of stock trading, few analysts command as much attention as Jim Cramer, the host of CNBC’s "Mad Money". Recently, he has made headlines for his cautious stance on IonQ (IONQ), a player in the burgeoning quantum computing sector, while simultaneously endorsing Kimberly-Clark (KMB) as a robust investment choice. Cramer’s analysis offers vital insights into navigating the stock market, especially as interest rates fluctuate and economic conditions shift.

On July 22, during a segment of "Mad Money", Cramer advised investors to stay away from IonQ, despite its impressive technology and growth potential. He expressed concerns about the current macroeconomic environment, particularly the effects of rising interest rates on high-growth stocks. In contrast, Cramer highlighted Kimberly-Clark’s recent acquisition of Kenvue as a strategic move that positions the company for stable long-term growth and profitability.

Understanding IonQ’s Market Position and Cramer’s Concerns

Quantum computing has emerged as one of the most exciting fields in technology, with promises of revolutionizing industries from cryptography to drug discovery. Yet, despite the enthusiasm surrounding companies like IonQ, Cramer’s reservations are rooted in a fundamental principle of finance: the impact of interest rates on company valuations.

The Rate Sensitivity of High-Growth Stocks

IonQ has faced significant volatility in its stock price, recently trading at around $33, down from a peak of $72 in late May. This decline can be attributed to a broader market trend, where rising interest rates make high-growth stocks like IonQ less attractive. As Cramer pointed out, these companies are valued based on their future cash flows, which are discounted more heavily in a high-rate environment. This compression in valuations is a well-documented phenomenon in financial markets.

The first quarter of 2026 saw IonQ report a staggering revenue increase of 755% year-over-year, totaling $64.7 million. However, with an expected Adjusted EBITDA loss of $310 million to $330 million for the year, Cramer argues that the gap between revenue and profitability makes IonQ a risky investment at this time. The company’s reliance on future earnings, combined with a challenging market, leads to a cautious outlook.

Kimberly-Clark: A Defensive Investment Strategy

In stark contrast, Cramer’s bullish view on Kimberly-Clark underscores a strategic shift for investors looking to balance their portfolios. The acquisition of Kenvue, the consumer health business spun off from Johnson & Johnson, is seen as a pivotal move for Kimberly-Clark.

The Kenvue Acquisition: A High-Margin Powerhouse

Cramer pointed out that Kimberly-Clark's purchase of Kenvue puts it in control of essential consumer products like Tylenol, Neutrogena, and Listerine. Such products typically enjoy consistent demand regardless of economic conditions, making Kimberly-Clark a stable investment option. The acquisition is expected to enhance revenue growth, improve operating margins, and streamline costs.

Moreover, Kimberly-Clark's current valuation presents a rare opportunity for investors. Trading at approximately 14 times this year’s earnings, the stock is near its lowest valuation in a decade, while offering a generous dividend yield of 4.74%. With a history of 54 consecutive years of dividend increases, Kimberly-Clark is classified as a Dividend King, making it a compelling choice for income-focused investors.

Market Reactions and Future Outlook

Investors are keenly awaiting Kimberly-Clark's upcoming second-quarter earnings report on August 4. While Cramer does not anticipate an explosive performance, he emphasizes that the stock is a reliable compounder, ideal for those looking to balance their portfolios by reallocating from high-risk technology stocks.

Institutional Confidence and Market Dynamics

Institutional investors hold a significant stake in Kimberly-Clark, with approximately 93.39% ownership. This backing provides a level of confidence for retail investors who may be hesitant about market volatility. However, the stock currently faces a high short interest of 14.56%, indicating some skepticism about its long-term growth prospects.

Despite this, Cramer argues that the combination of a strong product portfolio, stable cash flows, and a reasonable valuation makes Kimberly-Clark a more attractive investment compared to its peers in the consumer staples sector, such as Procter & Gamble and Colgate-Palmolive, which trade at premium multiples.

Key Takeaways

• Cramer advises caution with IonQ due to rising interest rates impacting high-growth stocks.
• Kimberly-Clark's acquisition of Kenvue positions it for stable growth and profitability as a defensive investment.
• Kimberly-Clark's valuation is attractive at 14 times earnings with a 4.74% dividend yield.
• Institutional backing adds confidence to Kimberly-Clark, despite high short interest.

Frequently Asked Questions

What makes IonQ a risky investment right now?

IonQ is experiencing significant volatility, with a steep decline in stock price after a peak earlier this year. Cramer highlights that rising interest rates are particularly detrimental for companies like IonQ, which rely heavily on future cash flows. As interest rates increase, the present value of those future earnings diminishes, leading to compressed valuations and increased investment risk.

Why is Kimberly-Clark considered a defensive investment?

Kimberly-Clark is seen as a defensive investment because it manufactures essential consumer products with stable demand, such as personal care and health items. The recent acquisition of Kenvue enhances its product portfolio and positions the company for consistent revenue generation, even in uncertain economic times. Additionally, its history of dividend increases offers a safety net for investors seeking reliable income.

What does the short interest in Kimberly-Clark indicate?

The elevated short interest in Kimberly-Clark, currently at 14.56%, suggests that some investors are skeptical about the company's long-term growth prospects. However, Cramer notes that this short interest is part of a merger arbitrage strategy related to the Kenvue acquisition, where investors are hedging their bets on the merger’s outcome rather than indicating a fundamental weakness in Kimberly-Clark's business model.

What impact could the upcoming earnings report have on Kimberly-Clark's stock?

The upcoming earnings report is crucial for Kimberly-Clark, though Cramer does not expect it to be a major catalyst for stock price movement. Instead, he views the stock as a long-term investment opportunity. If the report shows steady performance, it could reassure investors and potentially lead to a more favorable outlook in the market. Conversely, any disappointments could lead to short-term volatility, but Cramer encourages investors to view such dips as buying opportunities.

This content is educational, not financial advice.